The Placebo Effect and Liver Health: Unlocking the Inner Pharmacy

Weight-loss medications, such as Ozempic and Wegovy, are currently under significant scientific scrutiny. Recent research indicates these drugs may treat serious liver conditions, with positive outcomes observed even in patients receiving a placebo.

Researchers examined a cohort of patients with metabolic dysfunction-associated steatohepatitis (MASH) - a severe condition caused by hepatic fat accumulation linked to obesity. Two thirds of participants received semaglutide weekly, while the remainder received a placebo.

Outcomes for the primary group were significant:

• Hepatic inflammation reduction: Nearly 63% of semaglutide participants showed marked improvement.
• Fibrosis regression: 37% exhibited a reduction in liver scarring.

However, the placebo group yielded unexpected data. 34% of participants experienced a reduction in liver inflammation, and 22% showed a decrease in fibrosis.

The fact that one third of patients experienced histologically confirmed hepatitis resolution without worsening fibrosis - objective cellular improvement achieved via a placebo - points to a potent connection between consciousness and physiology. These figures are often categorized as statistical noise; however, they represent a significant signal. The placebo effect challenges the paradigm where healing is exclusively exogenous. It indicates that the primary healing resource resides internally.

We possess an internal pharmacy capable of producing measurable biochemical changes through expectation, belief, and intent. This capacity is substantial. We do not require decades for a complete mechanical decryption of this process to utilize it. We can integrate the placebo effect into practice today through attention training, imagination, and belief management.

The key to understanding this phenomenon lies in active, purposeful application. Engaging with this process facilitates a deeper exploration of the mind-body interface. It provides not only a method for self-healing but a framework for self-understanding.

Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., ... & Ratziu, V. (2025). Phase 3 trial of semaglutide in metabolic dysfunction–associated steatohepatitis. New England Journal of Medicine.